The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InAmid intensifying competition in the global obesity treatment market, Novo Nordisk faced selling pressure as signs of slowing momentum emerged in a key growth driver. The company's shares declined by 2.5% to DKK319.20 following a report from Deutsche Bank. Weekly US prescription data pointed to a continued slowdown in the oral version of the Wegovy weight-loss drug, triggering investor concerns regarding the growth trajectory of the company's appetite-suppressing franchise.
This decline occurs as competition heats up with Eli Lilly, which recently reported robust performance for its rival drug Zepbound, with research indicating a growing market share in the GLP-1 segment (per market data). While Novo Nordisk maintains a dominant position, the slowdown in oral pill prescriptions is a sensitive indicator, as investors have high expectations for the convenience of oral administration to expand the consumer base beyond injectable treatments.
Regarding market performance, NVO shares in New York stood at $49.64 (at close July 07, 2026), trading within a range of $49.31 to $50.44 during the session. Traders are now monitoring for further clinical data or regulatory updates that could restore momentum, while broader markets look toward upcoming catalysts such as the Australian interest rate decision and US employment data to gauge overall risk sentiment in the healthcare sector.